Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant
- Conditions
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT04899349
- Locations
- 🇺🇸
Washington Uni School of Med Siteman Cancer Center, Saint Louis, Missouri, United States
🇲🇾Novartis Investigative Site, Kuala Lumpur, Malaysia
Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT04887935
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 87727
- Registration Number
- NCT04882813
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Dapagliflozin on Volume Vascular Outcomes.
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Frank Ruschitzka
- Target Recruit Count
- 80
- Registration Number
- NCT04869124
- Locations
- 🇨🇭
University Heart Center Zurich, Zurich, Switzerland
Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Autotelicbio
- Target Recruit Count
- 38
- Registration Number
- NCT04856969
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 10
- Registration Number
- NCT04818034
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial
- Conditions
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2021-03-12
- Target Recruit Count
- 1167
- Registration Number
- NCT04796428
Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 25
- Registration Number
- NCT04792190
- Locations
- 🇺🇸
Maine Medical Center, Portland, Maine, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Effect of Dapagliflozin on LV Remodeling Post AMI
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Instituto Mexicano del Seguro Social
- Target Recruit Count
- 60
- Registration Number
- NCT04783870
- Locations
- 🇲🇽
Hospital de Cardiología, Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico
Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- G.Gennimatas General Hospital
- Target Recruit Count
- 350
- Registration Number
- NCT04780438
- Locations
- 🇬🇷
Cardiology Department, Athens General Hospital "G. Gennimatas", Athens, Greece, Athens, Greece
🇬🇷2nd Department of Cardiology, National and Kapodistrian University of Athens, Faculty of Medicine, Athens, Greece., Athens, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.